The effect of Levamizole on improvement of immune system is well known. Obviously, infection is one of the major causes of death in burned patients. If this drug could reduce the infection rates in burn victims, then the mortality rate would also be decreased. One hundred patients with more than 50%, 3rd degree burn of body surface area are randomly divided into two groups. Patients with electrical or chemical burns, medical illness or on chronic use of medications are excluded from the study. The hospital care for all patients is the same as for the standard medical and surgical treatments. In group one Levamizole 100 mg/day is added to the treatment plan. In group two this drug is not administrated. Age, sex, cause of burn, percentage of burn area, burn degree, and specific body area, mortality, hospital stay, operation frequency and blood transfusion are evaluated and compared.